grant
The Role of RNA Splicing in Non-Small Cell Lung Cancer
Organization VA VETERANS ADMINISTRATION HOSPITALLocation RICHMOND, UNITED STATESPosted 1 Apr 2026Deadline 31 Mar 2030
VANIHUS FederalResearch GrantFY2026AKTAPAF-3APAF3AbscissionAkt proteinAlternate SplicingAlternative RNA SplicingAlternative SplicingApaf-3 proteinApoptosis-Related Cysteine Protease Caspase 9Apoptosis-Related Cysteine Protease Gene Caspase 9ApoptoticApoptotic Protease Activating Factor 3Apoptotic Protease Activating Factor 3 GeneApoptotic Protease MCH-6Apoptotic Protease MCH-6 GeneAutomobile DrivingBiologicalCASP-9CASP9CASP9 ProteinCASP9 geneCRISPRCRISPR/Cas systemCancer BiologyCancer CauseCancer Causing AgentsCancer EtiologyCancer PatientCancer TreatmentCancersCarcinogensCaspase-9 GeneCause of DeathCell BodyCell Communication and SignalingCell SignalingCell modelCellsCellular OncogeneCellular modelCeramidesCessation of lifeCheckpoint inhibitorChemoresistanceChemotherapy and RadiationChemotherapy and/or radiationClinical TrialsClustered Regularly Interspaced Short Palindromic RepeatsCombined Modality TherapyDNA mutationDataDeathDevelopmentDiseaseDisease ProgressionDisorderDown-RegulationEarly-Stage Clinical TrialsEffectivenessElementsEventExcisionExposure toExtirpationFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFosteringFoundationsGenerationsGeneticGenetic ChangeGenetic defectGenetic mutationGoalsHealth Care SystemsHeterogeneous-Nuclear Ribonucleoprotein LHistologyHumanICE-LAP6ICE-LAP6 GeneICE-LAP6 proteinICE-Like Apoptotic Protease 6ICE-Like Apoptotic Protease 6 GeneImmune checkpoint inhibitorImmune mediated therapyImmunologically Directed TherapyImmunotherapyIncidenceInduction TherapyInfiltrationIntracellular Communication and SignalingIsoformsLKB1LKB1/STK11 GeneLaboratoriesLinkMCH6Malignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMalignant Tumor of the LungMalignant neoplasm of lungMch6 proteinMethodologyModern ManMolecularMolecular TargetMultimodal TherapyMultimodal TreatmentMutationMyeloid-derived suppressor cellsNEOADJNSCLCNSCLC - Non-Small Cell Lung CancerNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNon-Polyadenylated RNANon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaNuclearOncogene ActivationOncogenesisOncogensOutcomePD-1 antibody therapyPD-1 therapyPD1 antibody therapyPD1 based treatmentPI-3K/AKTPI3K/AKTPathway interactionsPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPhase 1 Clinical TrialsPhase I Clinical TrialsPhenotypePhosphorylationPrognosisProtein IsoformsProtein Kinase BProtein PhosphorylationProto-Oncogene Proteins c-aktProto-OncogenesPulmonary CancerPulmonary malignant NeoplasmPurinesPutative RNA-Binding RegionQuantitative RTPCRQuantitative Reverse Transcriptase PCRRAC-PK proteinRNARNA Binding DomainRNA Gene ProductsRNA Recognition MotifRNA SeqRNA SplicingRNA sequencingRNAseqRNP DomainRNP MotifRNP-1 SignatureRecombinantsRecurrenceRecurrentRegulationRemovalReportingResearchResistanceRibonucleic AcidRoleSTK11STK11 geneSafetyServicesSignal TransductionSignal Transduction SystemsSignalingSolid NeoplasmSolid TumorSplicingSurgical RemovalSurvival RateTherapeuticTobacco DependenceTranslatingTranslationsUnresectableValidationVariantVariationVeteransaPD-1 therapyaPD-1 treatmentaPD1 therapyaPD1 treatmentanti-PD-1 therapyanti-PD-1 treatmentanti-PD1 therapyanti-PD1 treatmentanti-cancer therapeuticanti-cancer therapyanti-programmed cell death 1 therapyanti-programmed cell death protein 1 therapybiologicbiological signal transductionbiophysical analysisbiophysical studiesc-ONCc-akt proteincancer microenvironmentcancer therapycancer-directed therapycaspase-9cellular targetingcheck point immunotherapycheck point inhibitor therapycheck point inhibitory therapycheck point therapycheckpoint immunotherapycheckpoint inhibitor therapycheckpoint inhibitory therapycheckpoint therapychemo/radiation therapychemoresistantchemotherapy and radiotherapychemotherapy resistancechemotherapy resistantclinical implementationcombatcombination therapycombined modality treatmentcombined treatmentdevelopmentaldrivingex-smokerflow cytophotometryformer smokergenome mutationhigh riskhnRNP Lhuman dataimmune check point inhibitorimmune check point therapyimmune checkpoint therapyimmune microenvironmentimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunosuppressive microenvironmentimmunosuppressive myeloid cellsimmunosuppressive tumor microenvironmentimproved outcomein vivo Modelinduction therapiesinhibitorinnovateinnovationinnovativeinsightliver kinase B1loss of functionlung cancerlung cancer cellmalignancymilitary servicemortalitymouse modelmulti-modal therapymulti-modal treatmentmurine modelmutantmyeloid suppressor cellsmyeloid-derived suppressive cellsnanoliposomalnanoliposomeneoplasm/cancernew chemical entitynew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyoncogenic agentpalliativepathwaypatient oriented outcomesphase I protocolpre-clinicalprecision medicineprecision-based medicinepreclinicalprogrammed cell death protein 1 therapyproto-oncogene protein RACproto-oncogene protein aktprotooncogeneqRTPCRrac protein kinaseradiation or chemotherapyrecruitrelated to A and C-proteinresectionresistance mechanismresistantresistant mechanismresponseside effectsocial rolestandard of caresuppressive myeloid cellstargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttobacco addictiontobacco dependenttooltranscriptome sequencingtranscriptomic sequencingtranslationtumortumor immune microenvironmenttumor microenvironmenttumor-immune system interactionstumorigenesisvalidations
Description preview
Significance to VA: Lung cancer (LC) is the leading cause of cancer death for US veterans (USvets). Non-small
cell LC (NSCLC) represents the majority of LCs with a poor 5-yr survival rate (~23%). NSCLC patients in the VA
Health Care System are increasing as USvets often acquire tobacco addiction during military service fostering a
large percentage…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click